Dlbcl Cancer. Diffuse large b cell lymphoma dlbcl is the most common type of non hodgkin lymphoma nhl in the united states and worldwide accounting for about 22 percent of newly diagnosed cases of b cell nhl in the united states. In an interview with cancernetwork armin ghobadi md of the washington university school of medicine in st.
Louis explained some of the exciting advances in the treatment of diffuse large b cell lymphoma dlbcl and hypothesized what s to come following the 2020 american society of hematology ash annual meeting exposition. Over 10 000 people are diagnosed with a type of nhl every year in the uk. Reid merryman md of the dana farber cancer institute spoke with cancernetwork to detail the study design for investigating the prognostic value of circulating tumor dna among patients with diffuse large b cell lymphoma dlbcl presented at the 2020 american society of hematology ash annual meeting exposition.
Most often the treatment is chemotherapy chemo usually with a regimen of 4 drugs known as chop cyclophosphamide doxorubicin vincristine and prednisone plus the monoclonal antibody rituximab rituxan.
Diffuse large b cell lymphoma dlbcl is the most common type of non hodgkin lymphoma nhl in the united states and worldwide accounting for about 22 percent of newly diagnosed cases of b cell nhl in the united states. Currently the standard of care for patients with relapsed. Diffuse large b cell lymphoma dlbcl is the most common subtype of non hodgkin lymphoma nhl. Diffuse large b cell lymphoma dlbcl tends to grow quickly.
